6572 RESULTS
Sort By:
PET Tracer Detects Synapse Loss Across Alzheimer’s Brain Multimodal Imaging of Neurodegenerative Diseases Links Pathology and Cellular Dysfunction Tau PET: The Field Expands Rapidly Can PET Match Up Areas of Protein Deposit With Alzheimer’s Symptoms? How
Synapse loss and mitochondrial stress, as seen by separate PET tracers, go hand-in-hand in Alzheimer’s, Parkinson’s, and frontotemporal dementia.
FDA approves adding safety and efficacy data from an Alzheimer’s trial to the drug’s label.
The creation of long-term memories requires a continual supply of myelin provided by newly formed oligodendrocytes. Alas, the generation of fresh oligodendrocytes diminishes with age, along with memory.
Vision improved in some retinitis pigmentosa patients in a Phase 1 trial.
At the HAI 2020 conference, the tracers PI-2620 and APN-1607 appeared to bind frontotemporal dementia tau. MK-6240 looked highly sensitive. And JNJ-067 and SNFT-1 are two new kids in town.
Amyloid and tau PET are helping scientists pinpoint the underlying cause of specific AD symptoms. Perhaps imaging of certain brain regions will help predict an individual’s progression.
At HAI 2020, scientists more precisely quantified the relationship between plaques, tangles, and cognitive decline.
By engaging scientists studying every tau-based disorder, a new conference aimed to foster collaborations and research directions.
Tau2020: Meeting for Tauopathies Debuts Genetic Variants Behold the First Human α-Synuclein CryoEM Fibril Structure New at Tau2020: PET Detects First Traces of Tangles in Rhinal Cortex Primary Tauopathies Get New PET Ligands Tau Receptor Identified on Cel
Not sure where that is? You are not alone. It is a tiny spot deep behind the nose, newly defined by the PET signal of early neurofibrillary tangle deposition. It also prompted a tau-staging scheme.
At Tau2020 conference, scientists implicate LDL receptor-related protein 1 in cell-to-cell transmission.
The monoclonal antibody activated TREM2 signaling on mouse microglia. It supported their survival and stimulated their clearance of amyloid plaques.
A survey conducted by the Alzheimer’s Association finds that three-quarters of these physicians had little to no residency training in dementia care.
United Kingdom’s DRI pivots to fight COVID-19. The facility could test 10,000 samples per day.
No filters selected
